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Background:  Cannabis  users  are  highly  likely  to  also  be  tobacco  cigarette  smokers  and  a proportion  of  this
comorbidity  is attributable  to  shared  genetic  inﬂuences.  Three  large  meta-analyses  of  genomewide  asso-
ciation  studies  (GWAS)  of  tobacco  smoking  have  identiﬁed  multiple  genomewide  signiﬁcant  (p  <  5 ×  10−8)
single nucleotide  polymorphisms  (SNPs).  We  examine  whether  these  SNPs  are  associated  with  tobacco
smoking  and  with  cannabis  involvement  in  an  independent  sample.
Method:  Eleven  SNPs  associated  with  cigarettes  per day  (CPD),  ever  versus  never  smoking  and  current
smoking/smoking  cessation  at p  < 5  ×  10−8 were  selected  from  three  published  meta-analyses.  Associ-
ation  analyses  were  conducted  with  similar  tobacco  smoking  measures  in  2716 European-American
subjects from  the  Study  of Addictions  Genes  and  Environment  (SAGE)  and  with  lifetime  and  current
cannabis  use  and DSM-IV  cannabis  abuse/dependence.
Results:  Cannabis  use  and  tobacco  smoking  correlated  at  0.54. Rs16969968  in  CHRNA5  (and  its  proxy,
rs1051730  in CHRNA3)  and  rs1451240,  a proxy  for rs13280604  in  CHRNB3,  were  associated  with
CPD  after  Bonferroni  correction  (p < 0.006).  rs1451240  was  also  associated  with  DSM-IV  cannabis
abuse/dependence.  Rs6265  in  BDNF  was  associated  with  smoking  initiation,  as  in the  original  meta-
analysis  and also  with  lifetime  cannabis  use.  Associations  with  cannabis  involvement  were  no longer
signiﬁcant  upon  adjustment  for the  tobacco  smoking  measures.
Conclusions:  The  modest  associations  between  cannabis  involvement  and  SNPs  for  tobacco  smoking
were  not  independent  of  the  comorbidity  between  tobacco  and  cannabis  involvement.  Larger  samples  of
individuals  might  be  required  to articulate  the speciﬁc  genetic  architecture  of  cannabis  involvement.
©  2015  Elsevier  Ireland  Ltd.  All  rights  reserved.. IntroductionCannabis and tobacco smoking frequently co-occur (Grant
t al., 2004). A proportion of this correlation between cannabis
nvolvement and cigarette smoking has been attributed to genetic
∗ Corresponding author at: Washington University School of Medicine, Depart-
ent of Psychiatry, 660 S. Euclid, CB 8134, St. Louis, MO 63110,
SA. Tel.: +1 314 286 1778; fax: +1 314 286 2213.
E-mail address: arpana@wustl.edu (A. Agrawal).
ttp://dx.doi.org/10.1016/j.drugalcdep.2015.02.029
376-8716/© 2015 Elsevier Ireland Ltd. All rights reserved.inﬂuences (Agrawal et al., 2012), with genetic correlations ranging
from 0.31 in an adolescent sample to 0.82 (in adults) (Huizink et al.,
2010; Neale et al., 2006; Young et al., 2006). One twin study also
noted that while cannabis and nicotine dependence are inﬂuenced
by different genetic factors, the correlation between these factors
is 0.82 (Kendler et al., 2007).
Despite evidence for genetic overlap, few studies have exam-
ined whether genetic variants implicated for one substance also
inﬂuence the other. Even though cannabis and tobacco have unique
pharmacological proﬁles, it is possible that pleiotropic effects
may  be responsible for shared aspects of their use and misuse,
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uch as experience of reward or attenuation of negative mood
tates. One approach for identifying such genetic variants is to
ocus on those that have been repeatedly identiﬁed in meta-
nalyses of genomewide association studies (GWAS; Duncan and
eller, 2011). As GWAS simultaneously examines a million or
ore single nucleotide polymorphisms (SNPs), in these analyses
nly SNPs with p-values of 5 × 10−8 are considered statistically
igniﬁcant. Consequently, the identiﬁcation of such SNPs typi-
ally necessitates large sample sizes. While there have not been
uch meta-analyses for cannabis involvement, three large meta-
nalyses of cigarette smoking have identiﬁed such signiﬁcant
NPs (Liu et al., 2010; Thorgeirsson et al., 2010; Tobacco and
enetics Consortium, 2010). In the present study, we selected
1 genomewide signiﬁcant SNPs associated with CPD, smoking
nitiation and smoking cessation/current smoking and exam-
ned: (a) whether they were associated with equivalent cigarette
moking measures in European-American subjects from an inde-
endent sample, Study of Addictions Genes and Environment
SAGE); and (b) whether the same SNPs were associated with
annabis use, current use and DSM-IV cannabis abuse/dependence
n SAGE, especially after accounting for comorbid cigarette
moking.
. Methods
.1. Sample
Data were extracted from SAGE, which drew data from three independent stud-
es to create a sample of unrelated DSM-IV alcohol dependent cases and alcohol
xposed controls (Bierut et al., 2010). Analyses focused on those of self-reported
uropean-American ancestry who also had genotypic data (N = 2716).
.2. Measures
All three parent studies (Begleiter et al., 1995; Bierut et al., 2007, 2008;
urnberger et al., 2004) used modiﬁed versions of the Semi-Structured Assessment
or  the Genetics of Alcoholism (SSAGA) to assess substance use and substance use
isorders (Bucholz et al., 1994). The current analyses utilized data on nicotine and
annabis related measures. For nicotine, these included smoking initiation (deﬁned
s  smoking 100 or more cigarettes during the lifetime; while this is also referred to
s  regular smoking, we use the term “smoking initiation” to be consistent with prior
eta-analyses of this phenotype), current tobacco use (currently using tobacco or
ast using a tobacco product within the year prior to the interview) and cigarettes
moked per day (CPD), deﬁned as a categorical variable (0 = 10 cigarettes or less;
 = 11–20; 2 = 21–30; 3 = 31 or more). Those who did not report smoking initiation
ere coded as missing for current smoking and CPD. For cannabis, items included
ver using cannabis, current use (currently using cannabis or last using cannabis
ith the year prior to the interview) and DSM-IV cannabis abuse/dependence, with
ifetime never users coded as missing for current use and abuse/dependence.
.3. Genotyping
As described in more detail in a previous publication (Laurie et al., 2010), geno-
ypic data were obtained from the Illumina Human 1M beadchip. For the current
nalyses, 11 SNPs were selected based on evidence for genomewide signiﬁcant
ssociation in three large meta-analyses (Table 1).
.4. Data analysis
Analyses were conducted using linear (CPD) and logistic (smoking and cannabis
nitiation, current use of cigarettes and cannabis, cannabis abuse/dependence)
egression models in PLINK (Purcell et al., 2007), with genotype coded log-additively
0, 1, 2 copies of the minor allele). Covariates included sex, age at interview, source
f study data and two principal components that accounted for any residual admix-
ure in those of European-American ancestry. Only SNPs associated with a speciﬁc
obacco smoking phenotype in the original meta-analyses were tested against that
henotype (e.g., rs6265 was  only tested for smoking initiation). Likewise, only SNPs
ssociated with any tobacco smoking measure were further tested with cannabis
nvolvement measures.. Results
The mean age of the sample was 38.7 [range 18–77 years]. Ever
moking even one cigarette (N = 2447) and ever using cannabispendence 150 (2015) 183–187
(N = 2017) was  reported by 90.1% and 74.2% of the sample, respec-
tively. Of those who had ever smoked, 84.5% reported smoking
100 or more cigarettes (smoking initiation; N = 2067). Current
smokers (N = 1391) and cannabis users (N = 622) comprised 67.3%
and 30.1% of those who  had smoked 100 or more cigarettes
and ever used cannabis, respectively. Of those who  had ever
used cannabis (N = 2017), 822 met  criteria for DSM-IV cannabis
abuse/dependence. In addition, for tobacco smoking, of those who
had smoked 100 or more cigarettes, 1030, 530 and 223 individ-
uals reported smoking ≥10, 11–20 and 21–30 CPD, respectively,
with the remainder reporting smoking >30 cigarettes. Of those
who had initiated smoking (N = 2067), 39.4% were nicotine depen-
dent by the Fagerström Test for Nicotine Dependence criteria (≥4
symptoms).
Among those who  had ever used cannabis, 96.7% ever smoked
cigarettes and 90.6% reported smoking initiation (r = 0.67). Of those
who reported current cannabis use, 85% were also current tobacco
users (r = 0.56). CPD scores (r = 0.47) and FTND (r = 0.54) were also
correlated with DSM-IV cannabis abuse/dependence.
Table 2 presents association results for the tobacco smoking and
cannabis involvement measures. After correction for multiple test-
ing, the data conﬁrmed previously reported associations between
rs6265 (BDNF) and smoking initiation and between rs16969968
(CHRNA5), rs1051730 (CHRNA3) and rs1451240 (CHRNB3) with
CPD. For cannabis, rs6265 was  associated with lifetime cannabis
use while rs1451240 was  associated with DSM-IV cannabis
abuse/dependence.
To examine whether the associations for cannabis involve-
ment were attributable to the comorbidity between smoking
initiation and ever using cannabis (for rs6265) and between
nicotine dependence (FTND; see Rice et al., 2012) and DSM-
IV cannabis abuse/dependence (for rs1451240), analyses were
repeated while including the tobacco measures as covariates.
In both instances, while effect sizes remained consistent (odds-
ratios for rs6265 and rs1451240 were 0.85 and 0.88 respectively),
the p-values were no longer signiﬁcant (p-value of 0.07 and
0.15, respectively). Regardless of adjustment for tobacco smoking,
rs6265 (adjusted R2 = 0.003) and rs1451240 (adjusted R2 = 0.004)
explained only modest proportions of variance in cannabis use and
abuse/dependence respectively.
4. Discussion
These analyses suggest that the association between cannabis
involvement and SNPs previously associated with tobacco smok-
ing in three large meta-analyses is modest and, quite likely, not
speciﬁc to cannabis involvement. Additionally, while the asso-
ciation between rs16969968/rs1051730 and tobacco smoking is
well-replicated (Bierut, 2011), these SNPs were not associated with
cannabis involvement (Culverhouse et al., 2014).
In contrast, our own  prior study (Rice et al., 2012) has found
support for the association between rs1451240 and FTND. This
SNP is a proxy for rs13280604 in CHRNB3 which was associated
at genomewide signiﬁcant levels (p = 2.4 × 10−8) with CPD in one
prior meta-analysis (Thorgeirsson et al., 2010) and has been impli-
cated in studies of nicotine dependence (Hoft et al., 2009b; Saccone
et al., 2007) as well as subjective reactions to nicotine (Ehringer
et al., 2010; Zeiger et al., 2008). The present study ﬁnds support for
a similar protective association for the same allele of this variant
and cannabis abuse/dependence. Being intronic, the functional sig-
niﬁcance of this SNP is unknown. This SNP has also been linked to
alcohol consumption (Hoft et al., 2009a) indicating its putatively
pleiotropic role across a host of substance-related behaviors.
Similarly, rs6265 in BDNF, a missense SNP (Val66Met), was asso-
ciated with smoking initiation and with lifetime cannabis use. In
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Table  1
Genomewide signiﬁcant single nucleotide polymorphisms (SNPs) from three meta-analyses of cigarette smoking.
SNP Chr; gene Phenotype; reference allele P-value Proxy required
TAG Consortium
rs1051730*,# 15; CHRNA3 CPD; G 2.8 × 10−73; 2.4 × 10−69
rs16969968* 15; CHRNA5 CPD; G 5.57 × 10−72
rs3733829 19; EGLN2 CPD; G 1.04 × 10−8
rs1028936 10; LOC100188947 CPD; C 1.29 × 10−9
rs4933206 10; LOC100188947 CPD; A 5.67 × 10−10 Proxy for rs1329650 (T);
r2 = 1.0
rs6265 11; BDNF Smoking initiation; T 1.8 × 10−8
rs3025316 9; near DBH Smoking cessation/Current
smoking; T
3.56 × 10−8 Proxy for rs3025343 (G);
r2 = 0.93;
Thorgeirsson et al.
rs1051730 15; CHRNA3 CPD; A 2.4 × 10−69
rs1451240 8; intergenic CPD; A 1.3 × 10−8 Proxy for rs13280604 (A)
in CHRNB3; r2 = 1.0
rs8102683 19; intergenic CPD; C 2.2 × 10−12 Proxy for rs4105144 (C);
r2 = 0.87
rs7937 19; RAB4B CPD; T 2.4 × 10−9
rs215605 7; PDE1 C CPD; G 5.4 × 10−9
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#o proxy found for rs6474412 (p = 1.4 × 10−8); r2 = 1.0 with rs13280604.
* SNPs in high LD, r2 = 1.0.
# Also identiﬁed by Liu et al.
he TAG meta-analysis, rs6265 was one of several genomewide
igniﬁcant SNPs associated with smoking initiation, however, its
enomewide signiﬁcance level was achieved only after sample
izes exceeded 143,000. In this context, the signiﬁcant p-value in
ur sample served as replication. Carriers of the A (Met) allele were
ess likely to smoke 100 or more cigarettes during their lifetime,
hich is consistent with the meta-analysis which reported that the
lternate G (or C) allele was associated with a 6% increase in relative
isk for smoking initiation. This SNP has been implicated in a wide
rray of psychopathology, most notably affective disorders, with
eta-analyses suggesting that the Met  allele is associated with
ncreased risk for major depressive disorder (Verhagen et al., 2010),
chizophrenia and eating disorders but decreased risk for substance
se disorders. We  see a similar protective effect of the Met  allele on
annabis use in this study (Table 2) and this decreased risk is consis-
ent with neurobiological models of stress response that implicate
his variant in blunted dopamine activity during reward processing
Pecina et al., 2014).
able 2
ssociation between previously identiﬁed genomewide signiﬁcant SNPs and tobacco and
SNP Reference
allele
Smoking
initiation
Current
smoking
CP
rs1051730* T – – 0.1
P =
rs16969968* A – – 0.1
P  =
rs3733829 C – – 0.0
rs1028936 C – – 0.0
rs4933206 C – – 0.0
rs6265 A# 0.76
[0.63–0.91]
P = 0.003
– – 
rs3025316 C – 0.94
[0.74–1.19]
– 
rs1451240 A## – – −0
P  =
rs8102683 T – – −0
rs7937 T – – 0.0
rs215605 G – – 0.0
Corrected
p-value
0.05 0.05 0.0
Alternate versus ##same allele as prior studies of smoking (see Table 1).
* Perfect linkage disequilibrium, r2 = 1; treated as one SNP for corrected p-value.It is also possible that the effect of rs6265 reﬂects Mendelian
randomization, in which the association between genotype and an
outcome (i.e., cannabis use) relates to individuals being “random-
ized” at birth to a higher likelihood of environmental exposure
(i.e., smoking initiation; Smith and Ebrahim, 2003). If carriers of
the G (Val) allele of rs6265 are more likely to initiate cigarette
smoking, and cigarette smoking, in turn, increases the likeli-
hood of cannabis initiation via environmental pathways, then the
association between rs6265 and cannabis use may reﬂect an envi-
ronmental process rather than evidence for genetic overlap. Due
to the rather general biological role of rs6265, these processes are
difﬁcult to disentangle.
Importantly, for both rs1451240 and rs6265, when smoking
initiation and FTND were included as covariates, the associations
with the cannabis measures were no longer statistically signiﬁ-
cant. While this might imply that the associations observed with
cannabis involvement are not independent of the associations
between these SNPs and tobacco-related outcomes, it is worth
 cannabis phenotypes in European-American subjects from SAGE.
D Cannabis use Current
cannabis use
DSM-IV
cannabis
abuse/dependence
00 (.03)
 0.001
1.03
[0.89–1.18]
0.98
[0.84–1.14]
0.91
[0.79–1.05]
01 (0.03)
 0.0009
1.03
[0.89–1.18]
0.97
[0.83–1.12]
0.92
[0.79–1.06]
67 (0.03) – – –
69(.04) – – –
46 (.03) – – –
0.82
[0.70–0.97]
P = 0.02
0.88
[0.73–1.07]
1.03
[0.86–1.24]
– – –
.101 (.04)
 0.005
1.17
[0.99–1.38]
0.83
[0.70–0.99]
P = 0.04
0.81
[0.68–0.96]
P = 0.01
.063 (.04) – – –
43 (.03) – – –
1 (.03) – – –
06 .017
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oting that the point estimates for and variance explained by
ach SNP remained relatively unchanged even after accounting for
obacco smoking. Therefore, it is possible that power to detect their
peciﬁc/independent effects on cannabis involvement was  attenu-
ted in this sample that is enriched for nicotine dependence.
One other study has utilized results from TAG to predict
annabis involvement in an independent sample. Vink and
olleagues (2014) used polygenic scores created by aggregating
NPs at varying p-value thresholds, up to p = 0.5, to predict tobacco,
lcohol and cannabis phenotypes in an independent Dutch sample.
uch an approach has the advantage of utilizing effects, even those
hat are not statistically signiﬁcant, to create a genetic predictor
hat is more consistent with the polygenic view of complex behav-
oral traits. The TAG polygenic scores for CPD were associated with
PD (p = 0.012 for TAG SNPs with p-value < 0.5) and cannabis use
p < 0.001) but the extent to which the most signiﬁcant SNPs (e.g.
s1051730) contributed to these ﬁndings is unclear. Our analyses
tudied these highly signiﬁcant individual SNPs that were part of
he polygenic scores and while we note a similar degree of asso-
iation with rs1051730, we do not see any association with other
AG SNPs (e.g. rs3733829). We  also extended the association to
annabis abuse/dependence, a phenotype that was not studied by
ink et al. (2014).
It is also worth noting that, for both tobacco smoking and
annabis involvement, SNPs associated with initiation (or life-
ime use) were not associated with later stages of CPD or
buse/dependence. Prior twin analyses have suggested substantial
verlap across genetic factors inﬂuencing initiation and problem
se of both tobacco and cannabis (e.g., Gillespie et al., 2009; Neale
t al., 2006). Nonetheless, evidence for genetic factors that only
nﬂuence later stages of tobacco dependence have also been iden-
iﬁed (Kendler et al., 1999; Neale et al., 2006) and is consistent
ith our results and those from the prior smoking meta-analyses
Table 1).
Some limitations of this study are worth noting. First, the
valuations focused only on European American subjects as the
eta-analyses were restricted to similar samples. Second, these
ata did not have a quantitative “CPD-like” measure of cannabis
se. Third, as the sample was enriched for alcohol dependence,
ates of cigarette smoking and cannabis involvement are higher
han those noted in the general population. This enrichment, par-
icularly as one of the contributing samples was ascertained for
icotine dependence (COGEND), may  have inﬂuenced our abil-
ty to detect these associations. Importantly, the associations with
annabis involvement should be viewed as preliminary and pend-
ng replication.
In conclusion, while analyses revealed some promising rela-
ionships of SNPs previously implicated in tobacco smoking with
annabis measures, these associations did not appear to be inde-
endent of their effects on smoking. As large meta-analyses of
obacco smoking have shown, by increasing sample sizes, com-
on  variants associated with cannabis involvement can also be
uccessfully identiﬁed. Such discoveries will enhance our ability
o identify such cross-disorder SNPs with greater precision, as has
een witnessed for phenotypes such as schizophrenia, bipolar dis-
rder, major depressive disorder and autism (Lee et al., 2013).
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